TScan Therapeutics, Inc. revenue breakdown overview

TScan Therapeutics, Inc. revenue for the last year amounted to 21.05 M USD, the most of which — 21.05 M USD — came from its highest performing source at the moment, T Cell Receptor-engineered T Cell, the year earlier bringing 13.54 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought TScan Therapeutics, Inc. 21.05 M USD, and the year before that — 13.54 M USD.